BWAY - BrainsWay: Still Undervalued (Still)

• In the past 12 months BrainsWay has received FDA clearance for the Theta Burst protocol and assisting smoking cessation as well as positive coverage policies for OCD.
• Insurance coverage for OCD strengthens BrainsWay’s position as the TMS market leader and confirms the potential of TMS outside of treating MDD.
• BrainsWay’s revenue growth could accelerate significantly as they begin to commercialize their installed base of OCD coils through revenue sharing arrangements.
• BrainsWay could also become the TMS supplier of choice, accelerating capital sales.
• These positive developments have still not been reflected in the share price, providing investors with an opportunity.

For further details see: